Equity Analysis /

IN : Healthcare - Overall - 1QFY23F diagnostics sector results preview

    12 July 2022
    Published byCGS-CIMB

    We expect our coverage universe to report revenue/EBITDA/PAT decline of 11%/29%/41% yoy and growth of 6%/11%/18% qoq, respectively, in 1QFY23F. Management commentary on market share churn, response strategy, new specialized tests, and organic geographical expansion are key monitorables. 1QFY22 had a very high base due to Covid 2.0. Hence, yoy comparison won’t be meaningful. Intense competition is a near-term risk. We stay Underweight.